Most importantly, we recently reported using a preclinical mouse model of meningioma; the systemic administration of CEP-1347, at a dose that was 1/10 the mouse equivalent of the dose safely administered to humans, was sufficient to effectively inhibit the growth of meningioma xenografts [13], suggesting the potential of CEP-1347 as a candidate wild-type p53-targeting agent for clinical applications. Here, TP53 is linked to meningioma.